Trial Search Results

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Jazz Pharmaceuticals


  • Drug: ADX-N05
  • Drug: Placebo


Phase 2


Inclusion Criteria:

   - Diagnosis of narcolepsy

   - Good general health

   - Willing and able to comply with the study design and schedule and other requirements

Exclusion Criteria:

   - If female, pregnant or lactating

   - Customary bedtime later than midnight

   - History of significant medical condition, behavioral, or psychiatric disorder
   (including suicidal ideation), or surgical history

   - Any other clinically relevant medical, behavioral or psychiatric disorder other than
   narcolepsy that is associated with excessive sleepiness

   - History of significant cardiovascular disease

   - Body mass index > 34

   - Excessive caffeine use - > 600 mg/day of caffeine or > 6 cups of coffee/day

   - History of alcohol or drug abuse within the past 2 years

   - Nicotine dependence that has an effect on sleep

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Paul Stowers